At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 31 enrolled
Drug / intervention
Tamoxifen +2 moredrug
Likely dose
Tamoxifen 20 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Selective Estrogen Receptor Modulators to Enhance the Efficacy of Viral Reactivation With Histone Deacetylase Inhibitors
National Institute of Allergy and Infectious Diseases (NIAID)·interventional·Posted Dec 26, 2017·Updated Jul 3, 2024
In Brief
A Phase 2 clinical trial evaluating Tamoxifen, Vorinostat, and 1 other intervention for HIV Infections. Completed, enrolled 31 participants across 15 sites in 2 countries.
Detailed Summary
This study evaluated the effects of tamoxifen exposure in combination with vorinostat on viral reactivation among HIV-1 infected post-menopausal women with virologic suppression on antiretroviral therapy (ART), when compared to vorinostat alone.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHIV Infections
CountriesPuerto Rico, United States
Collaborators--
Timeline
Phase 2CompletedFinished
201820192020202120222023202420252026
First PostedDec 2017
Enrollment StartApr 2018
Primary CompletionDec 2018
Study CompletionJul 2023
TodayJul 2026
First PostedDec 26, 2017
Enrollment StartApr 26, 2018
Primary CompletionDec 4, 2018
Study CompletionJul 27, 2023
TodayJul 2, 2026
Enrollment to primary: 7 monthsPosted 8.5 years ago
Interventions
Tamoxifendrug
20 mg orally
Vorinostatdrug
400 mg orally
Antiretroviral drugsdrug
Participants will receive antiretroviral drugs provided by their own doctors. Antiretroviral drugs will not be provided by the study.